31 May2024AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisAuthor By Healthufit Posted on May 31, 2024May 31, 2024AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the...